AstraZeneca PLC closed 14.73% below its 52-week high of £133.88, which the company achieved on September 3rd.

As AstraZeneca awaits an FDA decision for its Daiichi Sankyo-partnered Datroway in EGFR-mutated non-small cell lung cancer (NSCLC), the British pharma has rolled out early data from a trial ...

The best free Adobe Illustrator alternatives serve up all the essential tools artists need for vector editing without requiring a Creative Cloud subscription. There's ...

The best free logo maker is a great choice for those who need to create logos for their businesses without paying for subscriptions or licenses. I'll cut to the chase: for a free logo designer ...

Covington & Burling's London operation has advised pharmaceuticals giant AstraZeneca on its $1 billion acquisition of EsoBiotec, a Belgian biotechnology company specialising in vivo cell therapies.

Barclays analyst Emily Field maintained a Buy rating on AstraZeneca (AZN – Research Report) today and set a price target of £140.00. The company’s shares closed yesterday at p11,904.00.

AstraZeneca will leverage Alteogen’s platform technology to develop the therapies. Credit: © AstraZeneca 2025. AstraZeneca has entered an exclusive licence ...

AstraZeneca is set to acquire biotechnology firm EsoBiotec for up to $1 billion, including a $425 million upfront payment and up to $575 million contingent on milestones. EsoBiotec's ENaBL platform ...

AstraZeneca already has cell therapies in its pipeline, and it is now expanding its scope further with a deal to acquire EsoBiotec, a company in early clinical development with therapies made by ...

AstraZeneca has signed two deals worth $1.35 billion with Alteogen to develop subcutaneous versions of the British pharma’s cancer drugs despite a potential patent infringement risk. Monday, AZ ...

Bernstein analyst Justin Smith maintained a Buy rating on AstraZeneca (AZN – Research Report) today and set a price target of £190.00. The company’s shares opened today at p12,090.00.

EsoBiotec SA has entered into a definitive agreement to be acquired by AstraZeneca (NASDAQ:AZN) for up to $1 billion, on a cash and debt-free basis, it said on Monday. The deal includes an initial ...